52 related articles for article (PubMed ID: 19545630)
1. Intranasal administration of proteoliposome-derived cochleates from Vibrio cholerae O1 induce mucosal and systemic immune responses in mice.
Acevedo R; Callicó A; del Campo J; González E; Cedré B; González L; Romeu B; Zayas C; Lastre M; Fernández S; Oliva R; García L; Pérez JL; Pérez O
Methods; 2009 Dec; 49(4):309-15. PubMed ID: 19545630
[TBL] [Abstract][Full Text] [Related]
2. Mucosal immunization using proteoliposome and cochleate structures from Neisseria meningitidis serogroup B induce mucosal and systemic responses.
Campo JD; Zayas C; Romeu B; Acevedo R; González E; Bracho G; Cuello M; Cabrera O; Balboa J; Lastre M
Methods; 2009 Dec; 49(4):301-8. PubMed ID: 19410000
[TBL] [Abstract][Full Text] [Related]
3. A proteoliposome based formulation administered by the nasal route produces vibriocidal antibodies against El Tor Ogawa Vibrio cholerae O1 in BALB/c mice.
Pérez JL; Acevedo R; Callicó A; Fernández Y; Cedré B; Año G; González L; Falero G; Talavera A; Pérez O; García L
Vaccine; 2009 Jan; 27(2):205-12. PubMed ID: 18996426
[TBL] [Abstract][Full Text] [Related]
4. Robust gut associated vaccine-specific antibody-secreting cell responses are detected at the mucosal surface of Bangladeshi subjects after immunization with an oral killed bivalent V. cholerae O1/O139 whole cell cholera vaccine: comparison with other mucosal and systemic responses.
Shamsuzzaman S; Ahmed T; Mannoor K; Begum YA; Bardhan PK; Sack RB; Sack DA; Svennerholm AM; Holmgren J; Qadri F
Vaccine; 2009 Feb; 27(9):1386-92. PubMed ID: 19146897
[TBL] [Abstract][Full Text] [Related]
5. Cochleates derived from Vibrio cholerae O1 proteoliposomes: the impact of structure transformation on mucosal immunisation.
Acevedo R; Pérez O; Zayas C; Pérez JL; Callicó A; Cedré B; García L; Mckee D; Mullen AB; Ferro VA
PLoS One; 2012; 7(10):e46461. PubMed ID: 23077508
[TBL] [Abstract][Full Text] [Related]
6. Murine antibody responses following systemic or mucosal immunization with viable or inactivated Vibrio cholerae.
Nygren E; Holmgren J; Attridge SR
Vaccine; 2008 Dec; 26(52):6784-90. PubMed ID: 18951939
[TBL] [Abstract][Full Text] [Related]
7. Immune adjuvant effect of V. cholerae O1 derived Proteoliposome coadministered by intranasal route with Vi polysaccharide from Salmonella Typhi.
Acevedo R; Callicó A; Aranguren Y; Zayas C; Valdés Y; Pérez O; García L; Ferro VA; Pérez JL
BMC Immunol; 2013; 14 Suppl 1(Suppl 1):S10. PubMed ID: 23458379
[TBL] [Abstract][Full Text] [Related]
8. Intranasal immunization with recombinant toxin-coregulated pilus and cholera toxin B subunit protects rabbits against Vibrio cholerae O1 challenge.
Kundu J; Mazumder R; Srivastava R; Srivastava BS
FEMS Immunol Med Microbiol; 2009 Jul; 56(2):179-84. PubMed ID: 19453752
[TBL] [Abstract][Full Text] [Related]
9. Variable gene family usage of protective and non-protective anti-Vibrio cholerae O1 LPS antibody heavy chains.
Wade TK; Wade WF
Microbiol Immunol; 2008 Dec; 52(12):611-20. PubMed ID: 19120975
[TBL] [Abstract][Full Text] [Related]
10. Neonatal sublingual vaccination with Salmonella proteins and adjuvant cholera toxin or CpG oligodeoxynucleotides induces mucosal and systemic immunity in mice.
Huang CF; Wang CC; Wu TC; Wu KG; Lee CC; Peng HJ
J Pediatr Gastroenterol Nutr; 2008 Mar; 46(3):262-71. PubMed ID: 18376242
[TBL] [Abstract][Full Text] [Related]
11. Immunological properties of complex conjugates based on Vibrio cholerae O1 Ogawa lipopolysaccharide antigen.
Paulovicová E; Machová E; Hostacká A; Bystrický S
Clin Exp Immunol; 2006 Jun; 144(3):521-7. PubMed ID: 16734622
[TBL] [Abstract][Full Text] [Related]
12. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
13. [The study for the immuno-protection of E. coli O157:H7 outer membrane protein].
Zhang Y; Lu SQ; Zhang YZ; Zhao BX; Xu JG
Zhonghua Yi Xue Za Zhi; 2004 Jan; 84(1):58-62. PubMed ID: 14990161
[TBL] [Abstract][Full Text] [Related]
14. Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines.
Patel GB; Zhou H; Ponce A; Chen W
Vaccine; 2007 Dec; 25(51):8622-36. PubMed ID: 17959279
[TBL] [Abstract][Full Text] [Related]
15. [Intranasal priming with HIV DNA vaccine and systemic boosting with recombinant vaccinia induce vigorous immune responses: experiment with mice].
Huang XG; Xu JQ; Ren L; Qiu C; Zhang N; Liu LX; Wan YM; Peng H; Shao YM
Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(44):3109-13. PubMed ID: 17313761
[TBL] [Abstract][Full Text] [Related]
16. Mucosal immunity to HIV-1: systemic and vaginal antibody responses after intranasal immunization with the HIV-1 C4/V3 peptide T1SP10 MN(A).
Staats HF; Nichols WG; Palker TJ
J Immunol; 1996 Jul; 157(1):462-72. PubMed ID: 8683152
[TBL] [Abstract][Full Text] [Related]
17. A recombinant P4 protein of Haemophilus influenzae induces specific immune responses biologically active against nasopharyngeal colonization in mice after intranasal immunization.
Hotomi M; Ikeda Y; Suzumoto M; Yamauchi K; Green BA; Zlotnick G; Billal DS; Shimada J; Fujihara K; Yamanaka N
Vaccine; 2005 Jan; 23(10):1294-300. PubMed ID: 15652672
[TBL] [Abstract][Full Text] [Related]
18. Immunoglobulin A and CD8 T-cell mucosal immune defenses protect against intranasal infection with Chlamydia pneumoniae.
Rodríguez A; Rottenberg M; Tjärnlund A; Fernández C
Scand J Immunol; 2006 Mar; 63(3):177-83. PubMed ID: 16499570
[TBL] [Abstract][Full Text] [Related]
19. New vaccines require potent adjuvants like AFPL1 and AFCo1.
Pérez O; Lastre M; Cabrera O; del Campo J; Bracho G; Cuello M; Balboa J; Acevedo R; Zayas C; Gil D; Mora N; González D; Pérez R; González E; Barberá R; Fajardo EM; Sierra G; Solís RL; Campa C
Scand J Immunol; 2007; 66(2-3):271-7. PubMed ID: 17635804
[TBL] [Abstract][Full Text] [Related]
20. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein.
Olive C; Sun HK; Ho MF; Dyer J; Horváth A; Toth I; Good MF
J Infect Dis; 2006 Aug; 194(3):316-24. PubMed ID: 16826479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
